Cargando…
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available afliberce...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088480/ https://www.ncbi.nlm.nih.gov/pubmed/27847621 http://dx.doi.org/10.1186/s40942-016-0026-y |